
Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025
Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Medicine Alternative to Injectables for Obesity—at ADA Conference 2025 in Chicago SAN JOSE, CA, UNITED STATES, May 5, 2025 /EINPresswire.com/ -- Biomed Industries, Inc. (“ …